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Gained (LYG); Quality-Adjusted Life Years (QALY’s); long-term
costs; and cost-effectiveness for IDet vs. NPH. Standard
Markov/Monte Carlo simulation techniques were used to
describe incidence and progression of complications. Probabili-
ties of complications and HbA1c-dependent adjustments were
derived from the UKPDS and other major clinical trials and pop-
ulation studies. Clinical input was taken from a 6-month multi-
centre, multinational, open-label, parallel-group comparison
phase III trial in type-2 patients. Costs of treating complications
in the UK and utility values were retrieved from published
sources. Direct costs of diabetes complications and drug treat-
ment were projected over patients’ lifetimes from a UK National
Health Service perspective. RESULTS: The model projected that
treatment with IDet would result in an extra 0.13 LYG and 0.08
QALYs per patient. Total lifetime costs/patient were estimated to
increase by £1534. The cost per LYG was calculated to be 11,700
GBP and the cost per QALY to be £19,218. CONCLUSIONS:
The model predicted that treatment with IDet would result in
long term improvements in health outcomes and quality of life
compared to NPH in patients with type-2 diabetes. The cost-
effectiveness result is within the range considered to represent
value for money in the UK.
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OBJECTIVES: To examine the diabedic type-2 cost predictors.
METHODS: A total of 303 patients diagnosed with type-2 dia-
betes mellitus (mean age: 61, mean time from diagnosis: 10.86
year, males: 49%), were randomly selected from out-patients
charts databases and surveyed. Both patient and practitioner
questionnaires collected data from each patient on: clinical char-
acteristic, medical and other resources used, quality of life. Step-
wise linear regression model was elaborated to determine most
signiﬁcant clinical variables associated with cost. Values are
expressed in PLN (PLN1 = 0.4808€ PPP’2003). RESULTS: The
total annual treatment costs amounted to PLN9227 (4436€),
including PLN2432 (1169€) of direct costs. The regression
model incorporating complications, insulin treatment and man-
aging physicians’ specialty predicted direct costs associated with
diabetes best. Estimates were statistically signiﬁcant at p-level
0.05 and consistent with domain knowledge. Diabetologists’
patients generated lower mean direct treatment costs (PLN2140;
1028€) when compared to GP’s (PLN 2920; 1403€) for patients
of similar clinical characteristic. Controlling for case-mix dia-
betologists were more likely to increase drug cost balanced by
higher savings resulting from hospitalizations cost. CONCLU-
SIONS: Economic impact of diabetes type-2 is highly determined
by complications, insulin treatment and managing physicians’
specialty. Specialists (diabetologists) produce savings in direct
treatment costs which result from effective disease control with
drugs.
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OBJECTIVES: The installation of disease management programs
(DMP) is accompanied by expectations of high gains in health
and savings. This study estimates the potential gains of a DMP
for patients with type-2-diabetes for Germany under real life
conditions. METHODS: Representative data from the Germany
National Health Survey contained 307 subjects with type-2-dia-
betes, covering demographics, medical history, risk factors, and
treatment. Estimates for the risk to suffer from different com-
plications in the next ten years under given risk factor proﬁles
have been calculated using a validated prognosis model (Mel-
libase). Alternative risks have been calculated under the assump-
tion that in a DMP patients will reach individual risk factor levels
depending on their actual levels. Furthermore, assumptions have
been made for the patients’ persistence on a DMP scheme over
a 10-year period. Monetary savings for avoided complications
have been calculated using claims data of a German sickness
fund. RESULTS: In Germany there are 3.0 million patients with
known type-2-diabetes. Within the next ten years 18.9% of them
will suffer from a ﬁrst myocardial infarction, 19.2% from a ﬁrst
stroke. This will result in an average number of MIs of 56,000
and 57,000 strokes per year. About 2300MIs and 2000 strokes
are estimated to be avoided per year. Savings from avoided com-
plications will be approximately 120 million Euros per year. It
is estimated that the costs to run a DMP will exceed these
savings. CONCLUSIONS: Predicted health beneﬁts from a DMP
addressing all Type-2-diabetics are moderate in the actual
German health care system. Risk stratiﬁcation driven by prog-
nostic modeling is likely to improve this balance, if implemented.
Finally, the results underline that DMPs as other health 
technologies, need to be evaluated before their broad 
implementation.
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OBJECTIVES: In Ukraine, 800,000 Type-2 diabetic patients reg-
istered. Treatment state costs type 2 diabetes in Ukraine amount
to more than 36 billion GRN (1 Euro = 6.2GRN) per year,
mainly because of related complications. These complications
should be reduced at least by one-third by treating accordinng
to current guidelines. METHODS: The European Diabetes
Policy Group guidelines were applied to deﬁne the optimal
therapy regarding blood glucose, lipids and blood pressure.
Costs of guideline-related medication (antidiabetic drugs) and
costs of additional outpatient treatmant were calculated using
ofﬁcial tariffs. RESULTS: Guideline treatment would induce
1300GRN cost per patient for additional medication and out-
patient treatment. The phisicians prescribed glibenclamid
(maninil) 45% patients, metformin -18%, combined therapy 
-15%, insulin -22%. CONCLUSIONS: Treatment of patients
with type-2 diabetes according to the guidelines makes a huge
investment necessary. Assuming optimal treatment could prevent
25% diabetes-related complications and potential cost savings of
GRN 2 billion.
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OBJECTIVES: A recent randomized trial demonstrated that
twice daily biphasic insulin aspart 30/70 (BIAsp30/70) led to sig-
niﬁcantly (p = 0.0057) better glycaemic control compared to
bedtime insulin glargine in insulin-naïve type-2 diabetes patients
on oral antidiabetics (HbA1c reduced by -2.79% vs. -2.36%
from baseline). Patients gained more weight with BIAsp30/70
than with glargine (5.4 vs. 3.5kg, p = 0.0013), but weight gain
per unit insulin was similar. The CORE Diabetes Model, a peer-
reviewed, validated, model was used to project the long term cost
effectiveness of BIAsp30/70 versus glargine. METHODS: The
CORE Diabetes model employs standard Markov/Monte Carlo
simulation techniques to describe the long-term incidence and
progression of diabetes-related complications. Transition proba-
bilities were derived from major diabetes studies. Clinical effects
of comparators were derived from the INITIATE study. The
analysis was performed using published country-speciﬁc costs,
health care resource utilization and clinical data, and recom-
mended discount rates. A lifetime horizon and payers’ perspec-
tive was taken. Only direct costs were considered. Sensitivity
analyses were performed. RESULTS: Discounted quality-
adjusted life years (QALY) were improved by 0.13–0.25 years
with BIAsp30/70 versus glargine depending on country-speciﬁc
discount rates. Lifetime cost savings were observed 
with BIAsp30/70 in the Danish, Dutch, Finnish, French, Nor-
wegian, Spanish, and Swedish settings. Overall costs were
increased with BIAsp30/70 versus glargine in the German and
UK settings, with incremental cost-effectiveness ratios of 3692€
and £1541/QALY gained respectively. Results were most sensi-
tive to changes in baseline HbA1c and to the relative costs of
BIAsp30/70 versus glargine. CONCLUSIONS: Improvements in
glycemic control outweighed the greater increase in body weight,
leading to improved quality-adjusted life expectancy with
BIAsp30/70 versus glargine. BIAsp30/70 was projected to lead
to overall cost savings or would be considered cost-effective
versus glargine, with costs/QALY falling well below commonly
accepted international thresholds.
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OBJECTIVES: Type-2 diabetes is a major health problem. 30%
of all patients being on dialysis suffer from a diabetic Endstage
Renal Disease (ESRD). The Angiotensin-2-Receptor-Blocker
(ARB) Irbesartan has proven its capability to prevent or delay
an ESRD. Based on the results of the multicentre double-blind,
randomized, placebo-controlled Irbesartan Diabetic Nephropa-
thy Trial (IDNT) the presented study aims to show that a treat-
ment of renal diseases in hypertensive type-2 diabetics with the
ARB Irbesartan is cost saving for the German health care system.
METHODS: A cost-effectiveness analysis from the German
payers’ perspective was conducted taking direct costs into
account. 1715 type-2 diabetics with hypertension and limited
renal function were included in IDNT (2.6 years, subgroup with
300mg/d Irbesartan). The patient number needed to treat (NNT)
to prevent one ESRD was the efﬁcacy parameter for this analy-
sis. Public sources were used for cost data and information on
dialysis and transplantation in diabetics with ESRD. Actual drug
prices were used taking into account discounts and co-payments
effective in Germany due to new legislation since January 2004.
Due to conservative calculation no discounting was performed,
follow-up treatment costs were not included. RESULTS: The
NNT for the primary endpoint ESRD calculated to 28 during
the study period of 2.6 years in IDNT. That means additional
treatment costs of €25,007.—lead to one prevented ESRD (incre-
mental cost-effectiveness-ratio). The prevented ESRD (82% dial-
ysis, 18% transplantation) is worth €45,766.—which shows a
beneﬁt for Irbesartan treatment of €20,758.—after 2.6 years or
€7984.—per year assuming a linear trend towards delay in
ESRD. A sensitivity analysis stated the robustness of the data.
CONCLUSIONS: Based on epidemiologic data our results
suggest savings for the German health care system of €3.2 billion
after 2.6 years if annually additional €681 million were invested
in the treatment of type-2 diabetics with Irbesartan.
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OBJECTIVES: To construct a lifetime model evaluating poten-
tial health beneﬁts and costs applying to Scottish Type-2 diabetes
mellitus patients initiating ﬁrst-line oral monotherapy, for whom
metformin is inappropriate because of contra-indications or
intolerance. When lifestyle modiﬁcation (diet and exercise)
affords inadequate glycaemic control, these patients currently
have no alternative to sulphonylurea (SU) therapy. The model
compared novel agent pioglitazone (PIO) versus generic SU treat-
ment. METHODS: A decision-analytic Markov model was 
constructed using published (UKPDS) cost data for diabetes
management and co-morbidity treatment. Three prospective
treatment pathways were explored: ﬁrst-line PIO/second-line
PIO + SU combination/third-line insulin; ﬁrst-line SU/second-
line PIO + SU combination/third-line insulin; and ﬁrst-line
SU/second-line insulin. The model incorporated efﬁcacy evidence
of glycaemic control under PIO and SU, measured as initial
HbA1c improvements and the rate of disease progression in
terms of HbA1c (the coefﬁcient of failure). RESULTS: Patients
treated with PIO achieved better HbA1c control and improved
serum lipid proﬁles, which translated into fewer diabetic com-
plications, better quality of life and improved overall survival.
Additional drug costs of PIO over SU were partly offset by lower
costs to treat and manage diabetes complications, and delayed
insulin therapy. The estimated incremental cost per QALY gained
of PIO was £2415 compared to SU (when followed by second-
line PIO/SU and third-line insulin therapy). The incremental cost
per QALY gained of PIO was £1514 compared to SU (when fol-
lowed by second-line insulin therapy). CONCLUSIONS: Clini-
cal trial evidence indicated superior glycaemic (HbA1c) control
in patients treated with PIO, in comparison with those treated
with SU. The model showed that PIO is a cost-effective inter-
vention and thus a valuable addition to ﬁrst-line treatment
options for patients intolerant and/or contra-indicated to met-
formin. Importantly, initiating PIO as second-line combination
treatment after ﬁrst-line SU in this patient group was less efﬁ-
cient than providing PIO monotherapy in a ﬁrst-line setting.
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OBJECTIVES: To develop a lifetime model of Type-2 diabetes
mellitus and its sequelae, to compare the costs and beneﬁts of
